Skip to main content

Table 5 Antidiabetic drug use, by maternal age, in livebirth pregnancies among women with pre-existing diabetes during 2001–2013 in the MSDD

From: Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system

 < 20 years20–24 years25–29 years30–34 years35–39 years40–44 years45–54 years
Total unique pregnancies404 (100%)1608 (100%)3545 (100%)4949 (100%)3745 (100%)1082 (100%)273 (100%)
Drug product/Class
 Any Antidiabetic Drug365 (90.35%)1419 (88.25%)3262 (92.02%)4635 (93.66%)3536 (94.42%)1010 (93.35%)261 (95.60%)
 Alpha-Glucosidase Inhibitors0 (0.00%)2 (0.12%)8 (0.23%)9 (0.18%)3 (0.08%)4 (0.37%)2 (0.73%)
 Amylin Analog1 (0.25%)3 (0.19%)14 (0.39%)17 (0.34%)6 (0.16%)3 (0.28%)0 (0.00%)
 Metformin87 (21.53%)311 (19.34%)1102 (31.09%)1906 (38.51%)1722 (45.98%)598 (55.27%)160 (58.61%)
 Dipeptidyl Peptidase-4 Inhibitors1 (0.25%)3 (0.19%)32 (0.90%)66 (1.33%)75 (2.00%)27 (2.50%)19 (6.96%)
 Glucagon-like Peptide-1 Receptor Agonists3 (0.74%)11 (0.68%)56 (1.58%)103 (2.08%)94 (2.51%)34 (3.14%)15 (5.49%)
 Meglitinide Analogs1 (0.25%)7 (0.44%)8 (0.23%)13 (0.26%)9 (0.24%)3 (0.28%)2 (0.73%)
 Sulfonylureas28 (6.93%)184 (11.44%)512 (14.44%)907 (18.33%)833 (22.24%)255 (23.57%)84 (30.77%)
 Thiazolidinediones14 (3.47%)64 (3.98%)181 (5.11%)246 (4.97%)187 (4.99%)68 (6.28%)40 (14.65%)
 Combination Products6 (1.49%)37 (2.30%)84 (2.37%)155 (3.13%)155 (4.14%)43 (3.97%)22 (8.06%)
 Insulin321 (79.46%)1237 (76.93%)2701 (76.19%)3767 (76.12%)2868 (76.58%)789 (72.92%)113 (41.39%)